Login to Your Account

Financings Roundup

Wednesday, April 13, 2011
Inhibitex Inc., of Atlanta, said underwriters for its recent public offering exercised their overallotment option in full for an additional 1.7 million shares priced at $4.10 apiece, adding net proceeds of $6.6 million. Total net proceeds from the public offering were $50.6 million and are expected to help support a Phase II trial of nucleotide polymerase inhibitor INX-189 in chronic hepatitis C and fund other R&D and corporate expenses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription